<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161355</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00021</org_study_id>
    <nct_id>NCT01161355</nct_id>
  </id_info>
  <brief_title>Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject</brief_title>
  <official_title>An Exploratory Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9668 With Respect to an Intra-venous Microdose of [14C]AZD9668 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the absolute bioavailability and to evaluate
      pharmacokinetic parameters of a single oral dose and a radiolabelled intravenous microdose of
      [14C]AZD9668 in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study to assess the absolute bioavailability of a single oral dose of
      AZD9668 with respect to an intra-venous microdose of [14C]AZD9668 in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute bioavailability and evaluation of pharmacokinetic parameters (AUC, AUC (0-t), Cmax, tÂ½, tmax, and MRT of of a single oral dose and a radiolabelled intravenous microdose of [14C]AZD9668</measure>
    <time_frame>Multiple Pharmacokinetic blood samples for up to 96 hours following drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD9668: Adverse events, clinical chemistry, haematology, urinalysis, vital signs, electrocardiogram, physical examination</measure>
    <time_frame>measured within 21 days of drug administration and up to 7 days following drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD9668</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets and intravenous (IV) dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>Tablets of AZD9668 and IV dose of [C14]AZD9668</description>
    <arm_group_label>AZD9668</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weight at least 50
             kg and no more than 100 kg.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically significant abnormalities at screening examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Marks-Konczalik</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharan Sidhu, MB ChB, BAO,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>February 8, 2011</last_update_submitted>
  <last_update_submitted_qc>February 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>microdose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

